Intranasal calcitonin withdrawn owing to cancer risk

Miacalcic Nasal Spray (calcitonin) is being withdrawn owing to an increased risk of cancer with long-term calcitonin use.

Calcitonin is no longer licensed for use in osteoporosis, and will only be available as a solution for injection and infusion.  | SCIENCE PHOTO LIBRARY
Calcitonin is no longer licensed for use in osteoporosis, and will only be available as a solution for injection and infusion. | SCIENCE PHOTO LIBRARY

A review of all available data (including two studies of an unlicensed oral calcitonin preparation, post-marketing safety data and randomised controlled studies) showed that patients treated with calcitonin for long periods of time were more likely to develop malignancies than those taking placebo. The increase in cancer risk varied from 0.7% for the oral formulation to 2.4% for the nasal formulation, the only preparation licensed for long-term use – to reduce the risk of vertebral fractures in postmenopausal osteoporosis.

Risk–benefit analysis

Taking into account the limited efficacy of calcitonin in osteoporosis, the EMA concluded that the benefits of calcitonin did not outweigh the risks in this setting. Patients currently being treated with intranasal calcitonin should be reviewed and switched to an alternative osteoporosis treatment in line with NICE recommendations.

Calcitonin injection

Injectable calcitonin (Miacalcic Injection) remains available for short-term use in the prevention of acute bone loss due to sudden immobilisation, and for the treatment of Paget’s disease and hypercalcaemia of malignancy. Use in Paget’s disease is now restricted to patients who do not respond to, or cannot tolerate, other treatments.

MHRA Drug Safety Update August 2012

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases